TB-500 · safety & side-effect profile · research use only
TB-500 side effects: what's actually known, and whose data it really is.
The most important thing to understand about TB-500 side effects is a distinction almost no listing makes: the reassuring clinical safety numbers you'll see quoted are not from TB-500 at all. TB-500 is a short synthetic fragment (Ac-LKKTETQ, amino acids 17–23) of Thymosin Beta-4, the natural 43-amino-acid protein — and it is the full-length parent peptide, not the fragment, that has actually been through human trials. No dedicated clinical safety study of TB-500 itself has ever been published. This page separates the parent-peptide trial data from the fragment sold as a research compound, lays out the animal evidence and the open theoretical questions, and keeps anecdote in its own tier. It is a summary of published research reproduced as a laboratory reference — not a human-use protocol and not medical advice.
The safety data isn't actually TB-500's
TB-500 is a synthetic heptapeptide — Ac-LKKTETQ, corresponding to residues 17–23 of Thymosin Beta-4 (Tβ4). Virtually all published human safety data belongs to full-length Tβ4, not to the fragment: the RGN-259 ophthalmic Phase 2/3 program (over 1,700 subjects, reported well-tolerated with no significant adverse effects) and a 2021 first-in-human Phase I of 84 healthy volunteers, where adverse events were mild-to-moderate with no dose-limiting toxicity or serious events. The fragment shares part of the sequence but differs structurally, so extrapolating that record onto TB-500 is an assumption, not a measured result.
About the compound →No dedicated human trial of the fragment
There is no peer-reviewed clinical safety study of TB-500 specifically. Preliminary reports from small cohorts describe it as generally well-tolerated with a profile similar to placebo, but there are no controlled human trials, no large cohorts, and no long-term data on the 17–23 fragment. The honest summary from independent anti-doping science is that TB-500 remains experimental: its human safety is inferred from a related molecule rather than established on its own.
Dosage reference →The angiogenesis and malignancy question
TB-500's proposed mechanism runs through actin sequestration and angiogenesis — promoting new blood-vessel growth. That raises a theoretical concern: pro-angiogenic signalling that aids repair could, in principle, also support tumour vascularisation, which is the standard reason such compounds carry caution in anyone with a known or suspected malignancy. Published preclinical toxicology has not identified tumour-promoting activity, and Tβ4's role in cancer biology is genuinely context-dependent — but carcinogenicity studies typically run only 18–24 months and cannot rule out effects on longer timescales.
Mechanism & research →Mechanism-based populations of concern
Because the fragment has no human safety trial of its own, the cautions are derived from mechanism and from the parent peptide's biology rather than from observed TB-500 outcomes. Reviewers flag known or suspected malignancy, pregnancy and breastfeeding (Tβ4 has established roles in embryonic development), active cardiovascular disease, and concurrent anticoagulant use or coagulation disorders as populations of particular concern. These are illustrative, mechanism-based flags — not a clinical contraindication list, because no approved indication exists.
Handling & reconstitution →Anecdotal reports and long-term unknowns
The 'side effects' repeated across forums — a temporary head-rush or lethargy after dosing, mild injection-site reactions, occasional fatigue — are anecdotal, self-reported, and not confirmed in any controlled trial of TB-500. Honest research framing keeps them separate from the trial and preclinical findings. Beyond that, the long-term effects of the fragment on angiogenesis and tissue remodelling are simply undefined: no extended human follow-up of TB-500 exists, and product purity in the unregulated research market varies between and within suppliers.
Half-life & clearance →Regulatory status and research-use framing
TB-500 is not FDA-approved for any indication; the FDA lists the Tβ4 fragment (LKKTETQ) among bulk drug substances that may present significant safety risks in compounding. The World Anti-Doping Agency prohibits TB-500 and thymosin beta-4 at all times as growth-factor substances. Everything on this page summarises published preclinical and parent-peptide research, reproduced as a reference for laboratory and in-vitro work — not a prediction of what any individual would experience, and not instructions for human use. Titan supplies TB-500 strictly as a research reagent, not for human or animal consumption. Nothing here is medical advice.
Lab testing & COA →The detail, in plain terms
What the evidence actually says, source by source.
TB-500's safety picture has to be read in tiers — and the first tier is a warning about attribution: most of the clinical numbers belong to the full-length parent peptide, not the fragment being sold. Keeping the parent-peptide data, the fragment's absence of trials, the animal evidence, and the open theoretical questions separate is the whole point. Reproduced here as a research reference, not medical or dosing advice.
- What TB-500 is
- Synthetic heptapeptide Ac-LKKTETQ (residues 17–23 of Thymosin Beta-4); a fragment of, not identical to, the natural 43-amino-acid protein.
- Human trials of TB-500 itself
- None published. No dedicated peer-reviewed clinical safety study of the fragment exists.
- Parent-peptide (Tβ4) human data
- RGN-259 ophthalmic Phase 2/3 (1,700+ subjects, no significant AEs reported) and a 2021 Phase I of 84 healthy volunteers (mild–moderate AEs, no dose-limiting toxicity or serious events).
- Anecdotal (non-trial)
- Temporary head-rush or lethargy, mild injection-site reactions, occasional fatigue — self-reported online, not confirmed in controlled trials.
- Theoretical concern
- Pro-angiogenic actin-binding mechanism raises a theoretical tumour-vascularisation concern; preclinical toxicology has not shown tumour-promoting activity, but long-term data is absent.
- Populations of concern
- Mechanism-based flags: malignancy, pregnancy/breastfeeding, active cardiovascular disease, anticoagulant use / coagulation disorders.
- Long-term safety
- Undefined — no extended human follow-up of the fragment has been published.
- Regulatory status
- Not FDA-approved; Tβ4 fragment (LKKTETQ) flagged among compounding bulk substances of concern; WADA-prohibited at all times.
Questions researchers ask
Before you order.
- Does TB-500 have side effects?
- No dedicated human safety trial of TB-500 has ever been published, so there is no controlled adverse-event record for the fragment itself. Small preliminary reports describe it as generally well-tolerated, and the related full-length peptide (Thymosin Beta-4) was well-tolerated in its clinical trials. Anecdotal, non-trial reports mention a temporary head-rush or lethargy, mild injection-site reactions and occasional fatigue, but these are self-reported and not confirmed by controlled studies. This is a research reference, not medical advice.
- Is the safety data for TB-500 real?
- It's real data — but mostly not about TB-500. The reassuring 'well-tolerated, no significant side effects' figures come from clinical trials of full-length Thymosin Beta-4 (Tβ4), such as the RGN-259 ophthalmic program and a 2021 Phase I in healthy volunteers. TB-500 is a short synthetic fragment (Ac-LKKTETQ) of that protein and has not been through the clinical pipeline. Treating the parent peptide's safety record as if it were the fragment's is an assumption, not a measurement.
- Can TB-500 cause cancer?
- No direct evidence of tumour-promoting activity has been documented in published preclinical or clinical research, and thymosin beta-4's role in cancer biology is context-dependent rather than simply oncogenic. The concern is theoretical: TB-500's pro-angiogenic mechanism could, in principle, support blood-vessel growth in existing tumours, which is why people with a known or suspected malignancy are the standard population of caution. Standard carcinogenicity studies run only 18–24 months, so longer-timescale effects remain unstudied.
- Are there human clinical trials on TB-500?
- Not on the TB-500 fragment. The published human trials — the RGN-259 Phase 2/3 ophthalmic studies, the Phase I safety study in 84 healthy volunteers, and cardiac studies — all used full-length Thymosin Beta-4, not the 17–23 heptapeptide sold as TB-500. The fragment's human data is limited to small preliminary reports, with no controlled trials or long-term follow-up.
- Is TB-500 banned?
- Yes, in sport. The World Anti-Doping Agency prohibits TB-500 and thymosin beta-4 at all times, in and out of competition, as growth-factor substances. Separately, TB-500 is not approved by the FDA for any use, and the Tβ4 fragment (LKKTETQ) appears among bulk drug substances the FDA has flagged as potentially presenting significant safety risks in compounding.
- Is TB-500 approved for human use?
- No. TB-500 is an unapproved research compound with no regulatory approval for human use and no completed human efficacy trial. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic or preventative use. The safety information on this page summarises published research and is not medical or dosing advice.